EUVIMEDEUVIMED entdecken
Crossref

Commentary on: ribozyme-activated RNA trans-ligation: an emerging strategy for large gene delivery in muscular dystrophies

Martin K. Childers, Hui-Chong Lau, Hichem Tasfaout

Rare Disease and Orphan Drugs Journal · 13.03.2026 · 5 (1)

DOI: 10.20517/rdodj.2025.35 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rare Disease and Orphan Drugs Journal, online erschienen am 13.03.2026. Verfasst von Martin K. Childers und 2 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene therapies for muscular dystrophies are limited by the large size of disease-associated genes, which exceed the packaging capacity of standard adeno-associated virus vectors. In a recent Science article, Lindley et al . introduced “StitchR”, a ribozyme-activated RNA trans-ligation platform designed to reconstitute full-length transcripts inside cells, thereby enabling expression of large therapeutic proteins. This commentary evaluates the StitchR platform in the context of existing dual-vector strategies, particularly split-intein systems that have advanced to human clinical trials. We review the mechanistic distinctions, comparative efficiency, and translational readiness of RNA versus protein-level reconstitution, and highlight key unknowns related to immunogenicity, efficiency, and fidelity. While StitchR represents a conceptually elegant and potentially transformative approach, its therapeutic relevance will depend on further validation in additional preclinical studies, regulatory engagement, and head-to-head comparisons with clinically advanced platforms.

Zitieren

APA

Childers, M. K., Lau, H., & Tasfaout, H. (2026). Commentary on: ribozyme-activated RNA trans-ligation: an emerging strategy for large gene delivery in muscular dystrophies. Rare Disease and Orphan Drugs Journal, 5(1). https://doi.org/10.20517/rdodj.2025.35

Vancouver

Childers MK, Lau H, Tasfaout H. Commentary on: ribozyme-activated RNA trans-ligation: an emerging strategy for large gene delivery in muscular dystrophies. Rare Disease and Orphan Drugs Journal. 2026;5(1). doi:10.20517/rdodj.2025.35

BibTeX
@article{Childers2026,
  author = {Childers, Martin K. and Lau, Hui-Chong and Tasfaout, Hichem},
  title = {Commentary on: ribozyme-activated RNA trans-ligation: an emerging strategy for large gene delivery in muscular dystrophies},
  journal = {Rare Disease and Orphan Drugs Journal},
  year = {2026},
  volume = {5},
  number = {1},
  doi = {10.20517/rdodj.2025.35}
}
Kostenlos starten →